News
VTRS
16.51
+0.79%
0.13
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive
Seeking Alpha · 4d ago
Viatris Price Target Announced at $20.00/Share by Leerink Partners
Dow Jones · 4d ago
Viatris Initiated at Outperform by Leerink Partners
Dow Jones · 4d ago
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
Benzinga · 4d ago
Leerink sees growth for Viatris, starts at Outperform
TipRanks · 4d ago
Viatris price target raised to $20 from $15 at Argus
TipRanks · 5d ago
Weekly Report: what happened at VTRS last week (0831-0904)?
Weekly Report · 6d ago
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Seeking Alpha · 09/05 15:05
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
NASDAQ · 08/31 15:10
Weekly Report: what happened at VTRS last week (0824-0828)?
Weekly Report · 08/31 09:38
3 Cash-Producing Stocks That Concern Us
Barchart · 08/31 08:18
17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years
Seeking Alpha · 08/28 15:17
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
NASDAQ · 08/27 17:06
Weekly Report: what happened at VTRS last week (0817-0821)?
Weekly Report · 08/24 09:38
Stock futures fall as tech stocks come under pressure
Seeking Alpha · 08/24 08:03
Barclays Keeps Their Buy Rating on Viatris (VTRS)
TipRanks · 08/18 09:25
Is Buybacks And Higher 2026 Guidance Altering The Investment Case For Viatris (VTRS)?
Simply Wall St · 08/17 21:18
Weekly Report: what happened at VTRS last week (0810-0814)?
Weekly Report · 08/17 09:39
Einhorn’s DME Capital buys Fortune Brands, exits Peloton in Q2
TipRanks · 08/16 12:35
Viatris (VTRS) Could Be 12% Undervalued Following Raised 2026 Guidance
Simply Wall St · 08/16 00:27
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.